Navigation Links
CSA Medical Selected to Present at Mid-Atlantic Bio Conference

BALTIMORE, Oct. 28 /PRNewswire/ -- CSA Medical, Inc. ( has been selected to present the company's technology and business plans for its proprietary spray cryotherapy platform at the Mid-Atlantic Bio Conference. CSA Medical will be one of only eleven companies presenting in the emerging growth category. Twenty five companies in total will present across three categories. More than 800 national and international industry leaders, government representatives, executives, researchers, investors, entrepreneurs, and professional services firms will gather at the Mid-Atlantic Bio conference at the North Bethesda Marriott Convention Center in Bethesda, MD. CSA Medical will present on Thursday, October 28th at 2:20 pm when company executives, Ric Hughen and Steve Schaefer, will be on hand to present financial highlights, new product development and ongoing commercialization plans for CSA Medical's novel Spray Cryotherapy technology.

CSA Medical is first to harness the power of extreme cold, liquid nitrogen (-196 C), therapeutic energy delivery inside the body. This unique technology (device, catheter and agent) allows delivery of therapeutic doses of a cryogen to flash freeze and destroy diseased tissue inside the body.

"We are thrilled to be selected as this conference is hosted by some of the region's most influential bioscience and investor associations, including the Mid-Atlantic Venture Association (MAVA), the Tech Council of Maryland/MdBio (MdBio) and the Virginia Biotechnology Association (VaBIO)," said Steve Schaefer, the company's President and CFO. "This is quite an honor and reflects strong progress that the company has made gaining customers, treating over 6,000 patients and freezing disease."

The Mid-Atlantic Bio Conference, scheduled October 27-29, 2010, in Bethesda, Maryland, is co-hosted by the Tech Council of Maryland/MdBio (TCM/MdBio), the Mid-Atlantic Venture Association (MAVA), and the Virginia Biotechnology Association (VaBIO). Mid-Atlantic Bio benefits from broad regional support from the investor and greater business communities, academic institutions, government agencies, and partnering regional associations. For more information, or to register or sponsor, please visit

CSA Medical, Inc. develops and manufactures a proprietary therapeutic interventional platform, the CryoSpray Ablation™ System. The CSA System utilizes a patented spray cryogenic technology that allows a physician to freeze and destroy a wide range of unwanted tissues via an endoscope. Please visit for more information.

SOURCE CSA Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ZONARE Medical Systems Ranked Among Fastest Growing Companies By Silicon Valley Business Journal
2. Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services
3. OICR Makes Equity Investment in Medical Information Company
4. Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025
5. Philadelphia Eagles Offensive Lineman Todd Herremans Joins SPO Medical to Endorse New SPO Wellness(TM) Product Line
6. Clinical Genomics Pty Ltd and The Garvan Institute of Medical Research Enter into Licensing Agreement
7. Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors
8. 2010 Lasker Awards Honor Trailblazers in Medical Research and Clinical Care
9. IntriMed Technologies Launched to Address Challenges Faced by Medical Device Manufacturers
10. DSM Biomedical Announces Continued Partnership with Spinelab
11. NanoPass Technologies Ltd. and Elcam Medical Enter Into a Strategic Partnership
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... featured on AngelList early in their initial angel funding process. Now, they are ... individuals looking to make early stage investments in the microbiome space. In ...
(Date:11/24/2015)... /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended September 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of ... only value enriching for this clinical program, but ...
(Date:11/24/2015)... November 24, 2015 --> ... research report "Oligonucleotide Synthesis Market by Product & Services ... Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, ... MarketsandMarkets, the market is expected to reach USD 1,918.6 ... at a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... -- Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting ... Israel time, at the law offices of ... th Floor, Tel Aviv, Israel . ... Izhak Tamir to the Board of Directors; , election of ... approval of an amendment to certain terms of options granted to our ...
Breaking Biology Technology:
(Date:11/12/2015)... Mass. , Nov. 12, 2015  Arxspan ... Institute of MIT and Harvard for use of ... discovery information management tools. The partnership will support ... both biological and chemical research information internally and ... will be used for managing the Institute,s electronic ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):